Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, pilot, randomized, placebo-controlled trial of Gamunex-C IVIG as
mono-therapy for HMGCoA reductase auto-antibody positive (HMGCR) necrotizing myopathy. The
trial will test the feasibility and initial efficacy of Gamunex-C IVIG mono-therapy in HMGCR
necrotizing myopathy.